Performance of Commercially Antibody-based assays for Covid-19 Detection |Biomedgrid

The ongoing SARS-CoV-2 pandemic caused by novel coronavirus has become a threat to international public health. To tackle this pandemic reliable and rapid immunodiagnostic strategies are required. This study will briefly review the antibody diagnosis methods and recent clinical studies in this regard. The sensitivity and specificity after two weeks are considered to examine the late stages response of the disease. Among current studies on serology testing, 27 recent publications used commercial assays to diagnose IgM and IgG against SARS-CoV2 are discussed in this paper. A total of 54 kit-testing for antibodies, 20 are based on ELISA principles using serum or plasma samples with a sensitivity range of 55.6 % and 100% for IgG and between 77.3 % and 82.7 % for IgM. The specificity for both IgG and IgM ranges between 87.5 % to 100%. Twenty-seven kits are using lateral flow platforms and thirteen kits using luminescent immunoassays, including ten chemiluminescence immunoassay (CLIA) with sensitivity between 64 % and 97% for both IgM and IgG and 75.6% to 100% for IgG.